Table 3 Correlation of clinicopathologic characteristics and the twelve-gene signature in HCC

Follow-up time (mouths)

31.49 ± 25.24

21.85 ± 18.99

0.009

47.51 ± 18.72

34.36 ± 22.00

0.000

Risk score

1.23 ± 0.35

2.05 ± 0.25

0.000

0.54 ± 0.22

1.29 ± 0.29

0.000

Age (years)

0.565

0.282

  ≤ 60

88 (50.0%)

26 (45.6%)

73 (77.7%)

101 (83.5%)

  > 60

88 (50.0%)

31 (54.4%)

21 (22.3%)

20 (16.5%)

Sex

0.008

0.595

 Female

50 (28.4%)

27 (47.4%)

14 (14.9%)

15 (12.4%)

 Male

126 (71.6%)

30 (52.6%)

80 (85.1%)

106 (87.6%)

BMI (kg/m²)

0.664

  < 25

93 (52.8%)

32 (56.1%)

–

–

 ≥ 25

83 (47.2%)

25 (43.9%)

–

–

G stage

0.000

 G1 + G2

111 (63.1%)

17 (29.8%)

–

–

 G3 + G4

65 (36.9%)

40 (70.2%)

–

–

Residual tumor

0.905

 R0

166 (94.3%)

54 (94.7%)

–

–

 Non-R0

10 (5.7%)

3 (5.3%)

–

–

AJCC stage

0.089

0.006

 I + II

150 (85.2%)

43 (75.4%)

81 (86.2%)

85 (70.2%)

 III + IV

26 (14.8%)

14 (24.6%)

13 (13.8%)

36 (29.8%)

Vascular invasion

0.000

 No

129 (73.3%)

23 (40.4%)

–

–

 Yes

47 (26.47%)

34 (59.6%)

–

–

AFP (ng/ml)

0.002

0.001

 < 300

144 (81.8%)

35 (61.4%)

64 (68.1%)

54 (44.6%)

  ≥ 300

32 (18.2%)

22 (38.6%)

30 (31.9%)

67 (55.4%)

Multinodular

0.214

 No

–

–

78 (83.0%)

92 (76.0%)

 Yes

–

–

16 (17.0%)

29 (24.0%)

Cirrhosis

0.575

 No

–

–

9 (9.6%)

9 (7.4%)

 Yes

–

–

85 (90.4%)

112 (92.6%)